These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 1322792)

  • 1. Rational design and molecular effects of a new topoisomerase II inhibitor, azatoxin.
    Leteurtre F; Madalengoitia J; Orr A; Guzi TJ; Lehnert E; Macdonald T; Pommier Y
    Cancer Res; 1992 Aug; 52(16):4478-83. PubMed ID: 1322792
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Azatoxin is a mechanistic hybrid of the topoisomerase II-targeted anticancer drugs etoposide and ellipticine.
    Cline SD; Macdonald TL; Osheroff N
    Biochemistry; 1997 Oct; 36(42):13095-101. PubMed ID: 9335572
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intoplicine (RP 60475) and its derivatives, a new class of antitumor agents inhibiting both topoisomerase I and II activities.
    Riou JF; Fossé P; Nguyen CH; Larsen AK; Bissery MC; Grondard L; Saucier JM; Bisagni E; Lavelle F
    Cancer Res; 1993 Dec; 53(24):5987-93. PubMed ID: 8261412
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of DNA topoisomerase II by azaelliptitoxins functionalized in the variable substituent domain.
    Tepe JJ; Madalengoitia JS; Slunt KM; Werbovetz KW; Spoors PG; Macdonald TL
    J Med Chem; 1996 May; 39(11):2188-96. PubMed ID: 8667362
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual topoisomerase I and II inhibition by intoplicine (RP-60475), a new antitumor agent in early clinical trials.
    Poddevin B; Riou JF; Lavelle F; Pommier Y
    Mol Pharmacol; 1993 Oct; 44(4):767-74. PubMed ID: 8232227
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of DNA topoisomerase II as an intracellular target of antitumor epipodophyllotoxins in simian virus 40-infected monkey cells.
    Yang L; Rowe TC; Liu LF
    Cancer Res; 1985 Nov; 45(11 Pt 2):5872-6. PubMed ID: 2996763
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sequence selectivity of topoisomerase II DNA cleavage stimulated by mitoxantrone derivatives: relationships to drug DNA binding and cellular effects.
    De Isabella P; Capranico G; Palumbo M; Sissi C; Krapcho AP; Zunino F
    Mol Pharmacol; 1993 May; 43(5):715-21. PubMed ID: 8388987
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Linker length in podophyllotoxin-acridine conjugates determines potency in vivo and in vitro as well as specificity against MDR cell lines.
    Rothenborg-Jensen L; Hansen HF; Wessel I; Nitiss JL; Schmidt G; Jensen PB; Sehested M; Jensen LH
    Anticancer Drug Des; 2001 Dec; 16(6):305-15. PubMed ID: 12375883
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Covalent attachment of ethidium to DNA results in enhanced topoisomerase II-mediated DNA cleavage.
    Marx G; Zhou H; Graves DE; Osheroff N
    Biochemistry; 1997 Dec; 36(50):15884-91. PubMed ID: 9398321
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibitory effects of the tyrosine kinase inhibitor genistein on mammalian DNA topoisomerase II.
    Markovits J; Linassier C; Fossé P; Couprie J; Pierre J; Jacquemin-Sablon A; Saucier JM; Le Pecq JB; Larsen AK
    Cancer Res; 1989 Sep; 49(18):5111-7. PubMed ID: 2548712
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Podophyllotoxin analogs: effects on DNA topoisomerase II, tubulin polymerization, human tumor KB cells, and their VP-16-resistant variants.
    Liu SY; Hwang BD; Haruna M; Imakura Y; Lee KH; Cheng YC
    Mol Pharmacol; 1989 Jul; 36(1):78-82. PubMed ID: 2546053
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction of topoisomerase II-mediated DNA cleavage by a protoberberine alkaloid, berberrubine.
    Kim SA; Kwon Y; Kim JH; Muller MT; Chung IK
    Biochemistry; 1998 Nov; 37(46):16316-24. PubMed ID: 9819224
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel carbamate derivatives of 4-beta-amino-4'-O-demethyl-4-desoxypodophyllotoxin as inhibitors of topoisomerase II: synthesis and biological evaluation.
    Duca M; Arimondo PB; Léonce S; Pierré A; Pfeiffer B; Monneret C; Dauzonne D
    Org Biomol Chem; 2005 Mar; 3(6):1074-80. PubMed ID: 15750651
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of eukaryotic DNA topoisomerase I and II activities by indoloquinolinedione derivatives.
    Riou JF; Helissey P; Grondard L; Giorgi-Renault S
    Mol Pharmacol; 1991 Nov; 40(5):699-706. PubMed ID: 1658605
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potentiation of topoisomerase inhibitor-induced DNA strand breakage and cytotoxicity by tumor necrosis factor: enhancement of topoisomerase activity as a mechanism of potentiation.
    Utsugi T; Mattern MR; Mirabelli CK; Hanna N
    Cancer Res; 1990 May; 50(9):2636-40. PubMed ID: 2158396
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DNA-topoisomerase inhibitors.
    D'Incalci M
    Curr Opin Oncol; 1993 Nov; 5(6):1023-8. PubMed ID: 8305535
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design of two etoposide-amsacrine conjugates: topoisomerase II and tubuline polymerization inhibition and relation to cytotoxicity.
    Arimondo P; Boukarim C; Bailly C; Dauzonne D; Monneret C
    Anticancer Drug Des; 2000 Dec; 15(6):413-21. PubMed ID: 11716434
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: a Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines.
    Sehested M; Wessel I; Jensen LH; Holm B; Oliveri RS; Kenwrick S; Creighton AM; Nitiss JL; Jensen PB
    Cancer Res; 1998 Apr; 58(7):1460-8. PubMed ID: 9537249
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The 1'-substituent on the anilino ring of the antitumor drug amsacrine is a critical element for topoisomerase II inhibition and cytotoxicity.
    Rene B; Fosse P; Khelifa T; Jacquemin-Sablon A; Bailly C
    Mol Pharmacol; 1996 Feb; 49(2):343-50. PubMed ID: 8632768
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual inhibition of topoisomerase II and tubulin polymerization by azatoxin, a novel cytotoxic agent.
    Solary E; Leteurtre F; Paull KD; Scudiero D; Hamel E; Pommier Y
    Biochem Pharmacol; 1993 Jun; 45(12):2449-56. PubMed ID: 8392342
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.